Gold Coast Health Plan’s (GCHP) goal is to help its providers gain compliance with their annual Managed Care Accountability Set (MCAS) scores by providing guidance and resources. This tip sheet will provide the key components to the MCAS measure, “Annual Monitoring for Patients on Persistent Medications (MPM).”

**Measure Description:** Measures the percentage of members 18 years of age and older who received at least 180 treatment days of ambulatory medication therapy for a select therapeutic agent during the measurement year and at least one therapeutic monitoring event for the therapeutic agent in the measurement year. The following rates will be reported:

- Annual monitoring for members on angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB).
- Annual monitoring for members on diuretics.

**Data Collection Method:** Administrative

### Annual Monitoring

<table>
<thead>
<tr>
<th>Ambulatory Therapeutic Agent (Medication)</th>
<th>Therapeutic Monitoring Event</th>
</tr>
</thead>
</table>
| ACE inhibitors or ARBs                   | At least one serum potassium and a serum creatinine therapeutic monitoring test. Any of the following will meet compliance:  
  - A lab panel test.  
  - A serum potassium test and a serum creatinine test.  
  *The tests do not need to occur on the same service date, only within the measurement year.* |

| Diuretic                                 | At least one serum potassium and a serum creatinine therapeutic monitoring test. Any of the following will meet compliance:  
  - A lab panel test.  
  - A serum potassium test and a serum creatinine test.  
  *The tests do not need to occur on the same service date, only within the measurement year.* |

**Codes used to identify therapeutic monitoring events.**

<table>
<thead>
<tr>
<th>Description</th>
<th>CPT</th>
<th>LOINC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lab Panel</td>
<td>80047, 80048,</td>
<td>12812-4, 12813-2, 2823-3, 2824-1, 29349-8, 32713-0, 39789-3, 39790-1, 41656-0, 51618-7, 6298-4, 75940-7, 82722-0</td>
</tr>
<tr>
<td></td>
<td>80053, 80069</td>
<td></td>
</tr>
<tr>
<td>Serum Potassium</td>
<td>80051, 84132</td>
<td>11041-1, 11042-9, 12195-4, 13441-1, 13442-9, 13443-7, 13446-0, 13447-8, 13449-4, 13450-2, 14682-9, 16188-5, 16189-3, 21232-4, 2160-0, 2163-4, 2164-2, 26752-6, 31045-8, 33558-8, 35203-9, 35591-7, 35592-5, 35593-3, 35594-1, 38483-4, 39355-0, 39956-8, 39957-6, 39958-4, 39959-2, 39960-0, 39961-8, 39962-6, 39963-4, 39964-2, 39965-9, 39966-7, 39967-5, 39968-3, 39969-1, 39970-9, 39971-7, 39972-5, 39973-3, 39974-1, 39975-8, 39976-7, 40112-5, 40113-3, 40114-1, 40115-8, 40116-6, 40117-4, 40118-2, 40119-0, 40120-8, 40121-6, 40122-4, 40123-2, 40124-0, 40125-7, 40126-5, 40127-3, 40128-1, 40248-7, 40249-5, 40250-3, 40251-1, 40252-9, 40253-7, 40254-5, 40255-2, 40256-0, 40257-8, 40258-6, 40264-4, 40265-1, 40266-9, 40267-7, 40268-5, 40269-3, 40270-1, 40271-9, 40272-7, 40273-5, 44784-7, 50380-5, 50381-3, 51619-5, 51620-3, 59826-8, 59834-2, 62425-4, 62425-4</td>
</tr>
<tr>
<td>Serum Creatinine</td>
<td>82565, 82575</td>
<td></td>
</tr>
</tbody>
</table>
Important MPM Measure Specifications:
► Remember that the tests do not have to occur on the same service date; just make sure they are completed within the measurement year.
► Be mindful that patients can switch medications during the measurement year and have the days’ supply for those medications count toward the total 180 treatment days (e.g., a member who received 90 days of ACE inhibitors and 90 days of ARBs will meet the denominator definition).

Best Practices:
► Use the GCHP Performance Feedback Report to identify members with gaps in care.
► Make outreach calls and/or send letters to advise members on the need for a visit.
► Educate members about the importance of periodic testing.
► Review medications and assess for potential adverse drug effects (ADEs) at every visit.
► Order monitoring tests at least yearly.
► Remember: An increase in serum creatinine of >20%-30% or an abnormal serum potassium level may be indicative of decreased kidney function and warrants appropriate follow-up.
► More information is available from the National Kidney Foundation.
► For additional support with medication adherence and to gain an understanding of available local community resources, GCHP’s team of nurses, social workers, and care management coordinators can assist. Providers can contact the Care Management Department or refer patients / guardians / caregivers to the following contact information:
  • Providers, call: 1-805-437-5777
  • Members, call: 1-805-437-5656
  • GCHP website, Care Management: Click Here
► Ensure your documentation is clear and concise.
► Use proper coding.

1 Measures reported using the *administrative* data collection method report on the entire eligible population and use only administrative data sources (e.g., claims, encounter, lab, immunization registries) to evaluate if services were performed.